Wave Life Sciences' experimental obesity drug WVE-007 delivered disappointing results in its Phase I INLIGHT trial, causing the company's stock to crash 50%. The therapy showed only a 0.9% reduction in body weight and 3.3% decline in waist circumference compared to placebo in the study's highest dose cohort.
The INLIGHT trial (NCT06842186) evaluated WVE-007 in 32 participants with overweight or obesity conditions over a six-month follow-up period. The 240 mg dose cohort represented the highest dosage tested in this Phase I study designed to assess the drug's safety and initial efficacy signals in healthy individuals.
The minimal efficacy data represents a significant setback for Wave's obesity program, as investors had likely expected more substantial weight loss results to justify continued development. The company has not yet announced next steps for the WVE-007 program following these results.
The dramatic stock decline reflects investor disappointment with the modest weight loss achieved, particularly as the obesity drug market has seen substantial success with GLP-1 receptor agonists that can deliver weight reductions of 15-20% or more. Wave Life Sciences will need to reassess its obesity strategy given these underwhelming clinical results.
The poor trial outcome highlights the challenges facing biotech companies attempting to develop novel obesity treatments in a competitive landscape dominated by highly effective existing therapies.